Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience
Yafit Segman, Elena Ribakovsky, Abraham Avigdor, Yair Goldhecht, Vladimir Vainstein, Neta Goldschmidt, Shimrit Harlev, Netanel A. Horwitz, Odit Gutwein, Ronit Gurion, Gilad Itchaki, Uri Abadi, Anatoly Nemets, Orit Sofer, Miri Zektser, Tamar Tadmor, Nagib Dally, Kalman Filanovsky, Merav Leiba, Nadav Sarid, Noam Benyamini, Yair Herishanu, Ron Ram, Chava Perry, Irit Avivi
Abstract
The efficacy of polatuzumab vedotin in relapsed/refractory diffuse large B-cell lymphoma outside clinical study are undetermined. This retrospective study examined the efficacy and safety of polatuzumab vedotin administered in real life settings. Forty-seven patients, 31 with de-novo DLBCL and 16 with transformed lymphoma, treated with polatuzumab-based regimen in 14 Israeli centers between June 2018 and November 2019, were included. Median age was 66.1 years (60.4–78.8) and median number of prior lines was 3 (2–7). The overall response rate was 61% (n = 29), including 40% complete responses (n = 19) and 21% (n = 10) partial responses. The median overall survival and progression-free survival were 8.3 months and 5.6 months, respectively. An ECOG PS ≥2 predicted a decreased overall survival (p = 0.045). Primary refractory vs relapsed disease (p = 0.005) and transformed vs de-novo DLBCL (p = 0.039) were associated with shorter PFS (p = 0.027). Our data show that polatuzumab-based regimen is an effective and tolerable treatment in relapsed/refractory DLBCL.